Renalytix PLC on Thursday said that the US government has approved its authorised text kidneyintelX.dkd, to its government-wide acquisition contract for early-stage kidney disease bioprognostic testing services.
Shares in Renalytix rose 11% to 33.40 pence each in London on Thursday afternoon.
The London-based diagnostics company said the contract covers laboratory testing services provided by any government healthcare facility, including the US Veterans Administration, Department of Defense military branches, and Indian Health Services.
The kidneyintelX.dkd test provides risk-ratings for patients with chronic kidney disease and type-2 diabetes and establishes the possibility of rapid kidney function decline.
In June, the test received regulatory approval from the US Food & Drug Administration, and in October, Medicare established a pricing of $950 for the test.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
